Novavax, COVID-19
On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $14.42 which represents a decrease of $-0.26 or -1.77% from the prior close of $14.68. The stock opened at $14.07 and touched a ...
While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...
In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...
Shares of Novavax Inc. NVAX shed 5.62% to $13.61 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...
It is still a thing." Health Canada also approved the protein-based Novavax vaccine (Nuvaxovid) last week. It's designed to target JN.1, which is the dominant lineage in Canada at the moment.
Shares of Novavax Inc. NVAX shed 5.04% to $12.63 Monday, on what proved to be an all-around great trading session for the ...
The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...